Drug Trial Radar · NCT03326063
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban
Last checked: Nov 19, 2026Latest source record: Jul 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Apr 26, 2018
Primary completion
Mar 30, 2022
Study completion Apr 15, 2023
Sponsor
- Lead sponsor
- Brigham and Women's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 30, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall aim of the study is to determine the efficacy of oral ifetroban, a novel antagonist of T prostanoid (TP) receptors, as a treatment for patients with aspirin-exacerbated respiratory disease (AERD).
Conditions
- Nasal Polyps
- Asthma, Aspirin-Induced
- Aspirin-exacerbated Respiratory Disease
- Aspirin-Sensitive Asthma With Nasal Polyps
Interventions
IfetrobanDrug
4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
PlaceboDrug
4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Provocative Dose 2 (PD2) During Aspirin ChallengeTime frame: 6 weeks from screening visit ( at visit 2)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asthma Research Center, Brigham and Women's Hospital
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.